Semaglutide alleviated obesity-induced reproductive dysfunction in female mice by reducing ovarian inflammation, oxidative stress, and metabolic disruption through the SIRT1/SIRT6 signaling pathway.
Fertility restoredSemaglutide treatment reversed obesity-induced reproductive dysfunction including hormonal imbalance, ovarian damage, oocyte quality decline, and reduced fertility outcomes in female mice
What the researchers found
Obese (HFD) female mice showed insulin resistance, elevated NF-κB-associated pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), oxidative stress, reduced SIRT1/SIRT6/FOXO3a/NRF1/eNOS, elevated FOXO1/iNOS, decreased progesterone and estradiol, elevated FSH and LH, disrupted ovarian morphology, oocyte lipid accumulation and DNA damage, and reduced fertility.
Semaglutide treatment alleviated all of these dysfunctions: restoring SIRT1 and SIRT6 levels, reducing inflammation and oxidative stress, improving hormone balance, correcting ovarian structure, reducing oocyte damage, and improving fertility outcomes via modulation of the SIRT-associated pathway.
Why it matters
Obesity-related infertility affects millions of women worldwide and is becoming more common. This study shows semaglutide can improve fertility by directly addressing the ovarian damage caused by obesity — not just through weight loss but through specific anti-inflammatory and anti-oxidative mechanisms. This adds a fertility-related benefit to the already extensive list of semaglutide's therapeutic effects.
How the study worked
Female C57BL mice were divided into three groups: normal diet (NC), high-fat diet (HFD), and high-fat diet + semaglutide (HS). Assessments included body weight/composition, glucose/insulin/pyruvate tolerance, systemic and ovarian inflammatory cytokines, reproductive hormones, ovarian gene expression (SIRT1, SIRT6, FOXO1, FOXO3a, NRF1, IRS1, iNOS, eNOS, p27 KIP1, PTEN), ovarian histopathology, oocyte mitochondrial function, DNA damage, lipid/ROS levels, and fertility testing.
What this study cannot tell us
This was a mouse study using diet-induced obesity, which may not fully replicate human obesity-related infertility. It's unclear whether semaglutide's reproductive benefits come from weight loss alone or from direct ovarian effects independent of weight. The study did not assess whether semaglutide is safe to continue during pregnancy in mice. Specific semaglutide dosing was not detailed in the abstract.
How to read the evidence
This is a preclinical animal study with comprehensive mechanistic investigation spanning metabolic, inflammatory, and reproductive outcomes. While the breadth of endpoints assessed is impressive, all findings are from a mouse model and require human clinical validation.
When this study was published
Published in 2026, this is cutting-edge research addressing the timely question of how GLP-1 receptor agonists affect female reproductive function — crucial given the millions of reproductive-age women now using these drugs.
The bigger picture
This study adds reproductive health to the expanding list of organ systems benefited by GLP-1 receptor agonists. The finding that semaglutide works through the SIRT pathway — proteins associated with longevity and cellular protection — connects peptide therapeutics with fundamental cellular defense mechanisms. As GLP-1 drugs become widely used for weight management, understanding their reproductive effects is critical for the millions of reproductive-age women taking these medications.
Questions still open
- Does semaglutide improve fertility in obese women through similar SIRT-mediated mechanisms?
- Should semaglutide be discontinued before conception attempts, or could it improve pre-conception fertility without pregnancy risks?
- Do other GLP-1 receptor agonists produce similar ovarian-protective effects, or is this specific to semaglutide?
Common questions
How does obesity damage fertility?
Could semaglutide help women with obesity-related infertility?
Read the original research
GLP-1RA partially alleviates obesity-induced reproductive dysfunction driven by the interplay mechanisms of inflammation and metabolic dysregulation via the SIRT-associated pathway.
European journal of pharmacology, 1011, 178459
Citation
Matiki, Tashinga Walter; Ul Haq Shah, Mohd Zahoor; Yin, Lin; Liu, Rui; Zhu, Kejing; Lin, Zhongliang; Sheng, Jianzhong; Hefeng, Huang. (2026). GLP-1RA partially alleviates obesity-induced reproductive dysfunction driven by the interplay mechanisms of inflammation and metabolic dysregulation via the SIRT-associated pathway.. European journal of pharmacology, 1011, 178459. https://doi.org/10.1016/j.ejphar.2025.178459